MTOR and kidney neoplasm: PIK3CA and MTOR genes show gain-of-function mutations in about 2.5 and 6%, respectively, of renal tumors (COSMIC database), and the inhibition of the major effectors of the pathway (PI3K catalytic subunits, AKT, mTOR) is under intense exploration in clinical trials.